Journal of Clinical Psychopharmacology最新文献_第4页

Question: How Should I Switch From One Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to Another SSRI or SNRI in a Patient With Major Depressive Disorder? 问：重度抑郁障碍患者应该如何从一种选择性羟色胺再摄取抑制剂（SSRI）或羟色胺和去甲肾上腺素再摄取抑制剂（SNRI）切换到另一种 SSRI 或 SNRI？

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-22 DOI: 10.1097/JCP.0000000000001907

Anthony J Rothschild

引用次数: 0

Mania Associated With Cariprazine: A Case Report and a Review of Literature Regarding Bipolar Depression Treatment With Cariprazine. 与卡哌嗪有关的躁狂症：一份病例报告以及有关用卡普拉嗪治疗躁郁症的文献综述。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001892

Luís Pedro Paulino Ferreira, Carolina Martins Batista, João Carlos Machado Nogueira, Maria Amélia Silva Aleixo

引用次数: 0

Late Recognition of Cholinergic Delirium in Patient on Donepezil Combination Treatment. 多奈哌齐联合疗法患者胆碱能谵妄的后期识别。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-16 DOI: 10.1097/JCP.0000000000001901

Naomi Gwynn, Jean-Pierre Lindenmayer, Thomas Boes, Christian Pitalo

引用次数: 0

Comparison of Weight-Based Valproic Acid Dosing in Treatment of Mental Illness Among Obese and Nonobese Patients. 基于体重的丙戊酸剂量在治疗肥胖和非肥胖精神疾病患者中的比较。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCP.0000000000001883

Cindy Trac, Angeleki Zecopoulos, Clint Ross, Erin Weeda, Dan McGraw

{"title":"Comparison of Weight-Based Valproic Acid Dosing in Treatment of Mental Illness Among Obese and Nonobese Patients.","authors":"Cindy Trac, Angeleki Zecopoulos, Clint Ross, Erin Weeda, Dan McGraw","doi":"10.1097/JCP.0000000000001883","DOIUrl":"10.1097/JCP.0000000000001883","url":null,"abstract":"Purpose/background: A weight-based dosing approach of 20-30 mg/kg per day of valproic acid (VPA) has been shown to achieve rapid attainment of mood symptom control. Due to interindividual pharmacokinetic variability, therapeutic drug monitoring may be a useful tool to avoid VPA toxicity. Limited research exists on the impact of patient body weight on VPA pharmacokinetic profiles. This analysis aims to explore the correlation between steady-state serum levels of VPA and weight-based dosing strategies, including total body weight (TBW), ideal body weight (IBW), and adjusted body weight (AdjBW), between obese and nonobese patients.Methods/procedures: This single-center, retrospective, observational cohort analysis evaluated weight-based dosing of VPA in obese and nonobese patients admitted to inpatient psychiatry at a large academic medical center between July 1, 2017, and July 1, 2022.Findings/results: This analysis included 93 obese and 93 nonobese patients. No significant difference in median VPA serum concentrations was observed between groups ( P = 0.82). However, the obese group received a lower median weight-based dose (15.6 mg/kg) compared with the nonobese group (19.5 mg/kg, P < 0.001). A stronger correlation was found between VPA dose and therapeutic serum levels in the obese group compared with the nonobese group regardless of weight-based dosing strategy. Dosing with AdjBW in obese patients most closely approximated dosing with TBW in nonobese patients.Implications/conclusions: In obese patients, our analysis suggests dosing VPA using AdjBW may be considered as the preferred dosing strategy over IBW or TBW to minimize toxicity risk. Further research is needed with larger sample sizes and diverse patient populations to confirm these findings.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"468-471"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar Disorder. JNJ-18038683 对稳定型双相情感障碍患者的认知障碍缺乏疗效

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-09-01 DOI: 10.1097/JCP.0000000000001889

Mahdi Arshadi, Ahmed Z Elmaadawi, Suhayl Nasr, Karu Jayathilake, Stefanie Rassnick, Lisa Ford, Wayne C Drevets, Herbert Y Meltzer

{"title":"Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar Disorder.","authors":"Mahdi Arshadi, Ahmed Z Elmaadawi, Suhayl Nasr, Karu Jayathilake, Stefanie Rassnick, Lisa Ford, Wayne C Drevets, Herbert Y Meltzer","doi":"10.1097/JCP.0000000000001889","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001889","url":null,"abstract":"Background: The serotonin type 7 (5-HT7) receptor is one of 14 5-HT receptors. It has received attention for its possible role in mood disorders and cognition. The 5-HT7 receptor antagonist, JNJ-18038683, has been reported to be effective in rodent models of depression and REM sleep. Also, 5-HT7 receptor blockade has been postulated to be a key component of cognitive enhancement in a number of drugs. Bipolar disorder (BD) usually endures cognitive impairment (CI); however, no treatment for CI in BD has been approved. This study aimed to evaluate the efficacy of JNJ-18038683 to improve the CI of BD compared to a placebo.Methods: We conducted a placebo-controlled, 8-week trial of JNJ-18038683 in BD patients. Each patient's data were analyzed and reassessed blindly with a comprehensive neuropsychological battery, depression and hypomania ratings, and overall social and work function measures.Results: Of 60 patients, 38 (63%) were female, 43 (72%) had BD type 1, and most patients were Caucasian and married. The overall time effect for the combined group shows statistically significant improvement from baseline to week 8 for most of the neurocognitive battery measures. This indicates a significant improvement in psychopathology and cognition during the study time in both JNJ-18038683 and placebo groups, but no difference between groups.Conclusions: This study showed no efficacy for the improvement of CIBD or mood symptoms with JNJ-18038683 compared to the placebo.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"44 5","pages":"481-491"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Buprenorphine-Associated Behavioral and Psychotic Side Effects: A Case Report. 丁丙诺啡相关的行为和精神副作用：病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-08-28 DOI: 10.1097/JCP.0000000000001911

Felix Coid, Aikaterini Dima, Cecilia Livermore, Preety Das, Neeraj Kabra

引用次数: 0

Mirtazapine as a Treatment for Adolescent Depression and PTSD in Juvenile Detention Settings: A Case Report. 米氮平治疗青少年拘留所中的青少年抑郁症和创伤后应激障碍：病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-08-28 DOI: 10.1097/JCP.0000000000001905

Randall Li, Alexia Cicalese, Eric Whitney

引用次数: 0

Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia: A Post Hoc Analysis of the J-KINECT Study. 戊苯那嗪对日本老年和非老年迟发性运动障碍患者的疗效和安全性：J-KINECT 研究的事后分析》。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-08-27 DOI: 10.1097/JCP.0000000000001903

Yumi Watanabe, Yutaka Susuta, Mieko Nagano, Hideaki Masui, Nobuhisa Kanahara

{"title":"Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia: A Post Hoc Analysis of the J-KINECT Study.","authors":"Yumi Watanabe, Yutaka Susuta, Mieko Nagano, Hideaki Masui, Nobuhisa Kanahara","doi":"10.1097/JCP.0000000000001903","DOIUrl":"https://doi.org/10.1097/JCP.0000000000001903","url":null,"abstract":"Purpose: The efficacy and safety of valbenazine, a selective vesicular monoamine transporter 2 inhibitor, has been confirmed for treatment of tardive dyskinesia (TD) in patients aged ≥65 years in non-Asian clinical trials; however, data are lacking in elderly Asian patients. This post hoc analysis of J-KINECT aimed to evaluate the efficacy and safety of valbenazine in elderly Japanese patients with TD.Methods: J-KINECT was a randomized, double-blind, placebo-controlled study with a 6-week double-blind, placebo-controlled period; 42-week double-blind, valbenazine extension period; and 4-week posttreatment observation period. Outcomes were summarized by age (≥65 years [elderly] and <65 [nonelderly]) and treatment group.Results: The safety analysis set included 100 and 153 patients aged ≥65 and <65 years, respectively (intention-to-treat set: 98 and 151 patients, respectively). In the elderly group, the difference versus placebo in least-squares mean change from baseline in the Abnormal Involuntary Movement Scale total score at week 6 was -3.1 (95% confidence interval: -4.5, -1.7) and -5.5 (-7.0, -3.9) with valbenazine 40 and 80 mg, respectively; in the nonelderly group, respective differences were -1.5 (-2.6, -0.4) and -2.5 (-3.6, -1.3). Both age groups showed improvement in Clinical Global Impression of Change-Tardive Dyskinesia scores with valbenazine. The incidence of treatment-emergent adverse events (TEAEs) leading to treatment discontinuation was higher in the elderly versus nonelderly group. There was no trend toward higher incidences of TEAEs or related TEAEs in the elderly group.Conclusions: The findings suggest that valbenazine may be used effectively and safely as a treatment for TD, even in elderly patients.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atomoxetine Associated Activation Syndrome in Adolescent Patients With ADHD. 青少年多动症患者的阿托莫西汀相关激活综合征。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-06-21 DOI: 10.1097/JCP.0000000000001875

Harsh Khandelwal, Khushi Jain, Akshaya B Raj, Aakash Chahar, Surendra Singh Rajpurohit, Deepika Biyyala, Naresh Nebhinani, Navratan Suthar, Puneet Soni, Tanu Gupta

引用次数: 0

Preventive Effects of Ramelteon, Suvorexant, and Lemborexant on Delirium in Hospitalized Patients With Physical Disease: A Retrospective Cohort Study. 雷美替尼、苏伏雷康和伦博雷康对住院躯体疾病患者谵妄的预防作用：一项回顾性队列研究

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-06-03 DOI: 10.1097/JCP.0000000000001876

Ryuji Henmi, Tomoyuki Nakamura, Masaya Mashimoto, Fumitake Takase, Motohiro Ozone

{"title":"Preventive Effects of Ramelteon, Suvorexant, and Lemborexant on Delirium in Hospitalized Patients With Physical Disease: A Retrospective Cohort Study.","authors":"Ryuji Henmi, Tomoyuki Nakamura, Masaya Mashimoto, Fumitake Takase, Motohiro Ozone","doi":"10.1097/JCP.0000000000001876","DOIUrl":"10.1097/JCP.0000000000001876","url":null,"abstract":"Background: New sleep-inducing drugs (eg, ramelteon, suvorexant, and lemborexant) have been shown to prevent delirium in high-risk groups. However, no single study has simultaneously evaluated the delirium-preventing effects of all novel sleep-inducing drugs in hospitalized patients. Therefore, this study aimed to clarify the relationship between sleep-inducing drugs and delirium prevention in patients hospitalized in general medical-surgical settings for nonpsychiatric conditions who underwent liaison interventions for insomnia.Methods: This retrospective cohort study included patients treated in general medical-surgical settings for nonpsychiatric conditions with consultation-liaison psychiatry consult for insomnia. Delirium was diagnosed by fully certified psychiatrists using the Diagnostic and Statistical Manual of Mental Disorders 5 th edition. The following items were retrospectively examined from medical records as factors related to delirium development: type of sleep-inducing drugs, age, sex, and delirium risk factors. The risk factors of delirium development were calculated using adjusted odds ratios (aORs) via multivariate logistic regression analysis.Results: Among the 710 patients analyzed, 257 (36.2%) developed delirium. Suvorexant (aOR, 0.61; 95% confidence interval [CI], 0.40-0.94; P = 0.02) and lemborexant (aOR, 0.23; 95% CI, 0.14-0.39; P < 0.0001) significantly reduced the risk of developing delirium. Benzodiazepines (aOR, 1.90; 95% CI, 1.15-3.13; P = 0.01) significantly increased this risk. Ramelteon (aOR, 1.30; 95% CI, 0.84-2.01; P = 0.24) and Z-drugs (aOR, 1.27; 95% CI, 0.81-1.98; P = 0.30) were not significantly associated with delirium development.Conclusions: The use of suvorexant and lemborexant may prevent delirium in patients with a wide range of medical conditions.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"369-377"},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0